Adel Mahmoud, M.D., Ph.D. served as Chairman of ILiAD’s Scientific Advisory Board from 2013-2018 and provided extensive experience as a vaccine industry business executive, as well as expertise in vaccine science and development.
From 1999 to 2005, Dr. Mahmoud was President of Merck Vaccines and served as a member of the Management Committee of Merck & Company, Inc. At Merck, he also served as Chief Medical Advisor for Vaccines and Infectious Diseases. Dr. Mahmoud’s leadership resulted in Merck’s formidable vaccine portfolio, including commercialization of new vaccines for rotavirus, human papillomavirus, and shingles; and commercialization of a new combination vaccine for measles, mumps, rubella, and varicella.
His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. He was past President of the International Society for Infectious Diseases and former Chair of the Board of Scientific Counselors of the U.S. National Center for Infectious Diseases.
Dr. Mahmoud died on June 11, 2018 after a life of making major contributions to public health.